Download PDF
Thromb Haemost 1985; 54(03): 617-618
DOI: 10.1055/s-0038-1660082
Original Article
Schattauer GmbH Stuttgart

Urokinase Antigen in Plasma of Patients with Liver Cirrhosis and Hepatoma

J C Kirchheimer
*   The Laboratory for Clinical Experimental Physiologiy, Department of Medical Physiology, University of Vienna, Austria
,
K Huber
**   The II. Department of Gastroenterology and Hepatology, University of Vienna, Austria
,
P Polterauer
**   The II. Department of Gastroenterology and Hepatology, University of Vienna, Austria
,
B R Binder
*   The Laboratory for Clinical Experimental Physiologiy, Department of Medical Physiology, University of Vienna, Austria
› Author Affiliations
Further Information

Publication History

Received 09 April 1985

Accepted 25 July 1985

Publication Date:
19 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Plasma urokinase antigen levels were studied in 78 patients suffering from liver diseases. Blood was drawn before any specific medication was initiated. Impairment of liver function was comparable in all patients. In both groups of cirrhotic liver disease (alcoholic and non-alcoholic), normal levels of plasma urokinase antigen were found as compared to age-matched control groups. In both groups of patients with hepatomas (with or without a history of liver cirrhosis), however, significantly increased plasma urokinase antigen levels could be determined. These data indicate that an increase in plasma urokinase antigen might rather relate to malignant growth in liver disease than to impaired liver function.

Keywords

Urokinase antigen - Plasma prourokinase - Liver cirrhosis - Hepatoma
 

  • References

  • 1 Sherlock S. Diseases of the liver and biliary system (5th edition) Blackwell, London 1975
    PubMed
  • 2 Goodpasture EW. Fibrinolysis in chronic hepatic insufficiency. Bull Johns Hopkins Hosp 1914; 25: 330-335
    PubMedGoogle Scholar
  • 3 Finkbiner RB, McGovern JJ, Goldstein R, Bunker JR. Coagulation defects in liverdisease and response to transfusion during surgery. Am J Med 1959; 26: 199-204
    CrossrefPubMedGoogle Scholar
  • 4 Grossi CE, Moreno AH, Rousselot LM. Studies on spontaneous fibrinolytic activity in patients with cirrhosis of the liver and itsinhibition by epsilon amino capronic acid. Ann Surg 1961; 153: 383-393
    CrossrefPubMedGoogle Scholar
  • 5 Grossi CE, Rousselot LM, Pauke WF. Coagulation defects in patients with cirrhosis of the liver undergoing portasystemic shunts. Am J Surg 1962; 104: 512-516
    CrossrefPubMedGoogle Scholar
  • 6 Fletcher AP, Biederman O, Moore D, Alkjaersig N, Sherry S. Abnormal plasminogen-plasminsystem activity in patients withhepatic cirrhosis: its cause andconsequences. J Clin Invest 1964; 43: 681-695
    CrossrefPubMedGoogle Scholar
  • 7 Kwaan HC, McFadsean AJS, Cook I. Plasma fibrinolytic activity in cirrhosis of the liver. Lancet 1956; 1: 132-136
    PubMedGoogle Scholar
  • 8 Matsuo O, Kosugi T, Mihara H. Urokinase inactivation rate in the rabbit: effect of circulatory isolation of the liver, spleen and kidneys. Haemostasis 1978; 7: 367-372
    PubMedGoogle Scholar
  • 9 Korninger C, Stassen JM, Collen D. Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits. Thromb Haemostas 1981; 46: 658-661
    PubMedGoogle Scholar
  • 10 Booth NA, Anderson JA, Bennett B. Plasminogen activators in alcoholic cirrhosis: demonstrationof increased tissue type and urokinase type activator. J Clin Pathol 1984; 37: 772-777
    CrossrefPubMedGoogle Scholar
  • 11 Huber K, Kirchheimer J, Binder BR. Characterization of a specific anti-human urokinase antibody: development of a sensitive competition radioimmunoassay for urokinase antigen. J Lab Clin Med 1984; 103: 684-694
    PubMedGoogle Scholar
  • 12 Huber K, Kirchheimer J, Binder BR. Urokinase-type plasminogen activator in some gastrointestinal diseases - application of a specific radioimmunoassay for urokinase antigen. In: Clinical Aspects of Fibrinolysis and Thrombolysis Jespersen J, Kluft C, Korsgaard O. (eds.) Esbjerg: South Jutland University Press; 1983: 71-82
  • 13 Kirchheimer J, Binder BR. Urokinase antigen in plasma:age and sex dependent variations. Thromb Res 1984; 36: 643-646
    CrossrefPubMedGoogle Scholar
  • 14 Gelehrter TD, Baronski-Miller PA, Coleman PL, Cwikel BJ. Hormonal regulation of plasminogen activator in rat hepatomacells. Mol Cell Biol 1983; 53/54: 11-21
    PubMedGoogle Scholar
  • 15 Sherman LA, Lee JL, Stewart CC. Release of fibrinolytic enzymes by macrophages in response to soluble fibrin. J Reticuloendothel Soc 1981; 30: 317-329
    PubMedGoogle Scholar
  • 16 Vasalli JD, Hamilton J, Reich E. Macrophage plasminogen activator: modulation of enzyme production by anti-inflammatory steroids, mitotic inhibitors and cyclic nucleotides. Cell 1976; 8: 271-281
    CrossrefPubMedGoogle Scholar
  • 17 Kirchheimer JC, Pfluger H, Hienert G, Binder BR. Increased urokinase activityto antigen ratio in human renal cell carcinoma. Int J Cancer 1985; 35: 737-741
    CrossrefPubMedGoogle Scholar
  • 18 Korninger C, Wagner O, Binder BR. Tissue plasminogen activatorinhibitor (antiactivator) in human plasma: Development of a functional assay system and demonstration of a correlating Mr = 50000 antiactivator. J Lab Clin Med 1985; 105: 718-724
    PubMedGoogle Scholar